QV Alert -GeneDX Makes Exciting Appointment

A new chart breakout for GeneDX. A new appointment sounds exciting.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief Operating Officer, effective immediately. In the newly created role, Bryan will report to Katherine Stueland, CEO and President, and will serve on the company’s executive leadership team.

As Chief Operating Officer, Bryan will oversee Product & Technology, Operations, Medical Affairs, Innovation, and the Program Management teams at GeneDx. He will be pivotal in driving operational excellence as the company enters the next phase of commercial growth.

“Bryan’s extensive clinical, technical and operational experience and proven ability to lead scalable transformations will play a pivotal role in helping us execute our strategic vision and accelerate the adoption of genomic insights across healthcare,” said Stueland. “As we embark on the next phase of our growth and scale, I am confident Bryan’s leadership will be critical in helping us deliver impactful genomic insights and improve health outcomes for an ever-growing number of patients and families.”

GeneDX, 2 January 2025

The three slides below from the Q3 2024 presentation should help remind subscribers why GeneDX is such an exciting stock. The recent dramatic improvement in performance has come under the leadership of new CEO, Katherine Stueland and Bryan Dechairo looks an exciting addition to the top team.

This is what Dechairo said about his appointment.

“GeneDx has built a market-leading position in pediatric genetics and has an incredible opportunity to pave the way for the genomics revolution in healthcare today,” said Dechairo. “With world-class products, advanced AI and the most dynamic minds in the industry, I’m looking forward to supercharging operational excellence to accelerate profitable growth.”

GeneDx website, 2 January 2025

Share Recommendations (7 January 2025)

GeneDX. WGS